Building on our recent study in which we achieved synthetic lethality by combining paclitaxel with the EGFR inhibitor gefitinib in p53-null endometrial tumors [25], we first sought to verify that the loss of p53 function is required for this effect. The gene discussed is TP53; the disease is endometrium neoplasm.